popul
patient
cancer
organ
transplant
vasculitid
human
immunodefi
cienci
viru
hiv
infect
grown
intensivist
see
patient
alter
immun
patient
may
come
intens
care
unit
icu
lifethreaten
opportunist
infect
may
develop
lifethreaten
infect
icu
unrel
problem
intensivist
must
recogn
patient
differ
immunolog
normal
patient
term
clinic
present
manag
infect
chapter
emphas
import
way
immunosuppress
patient
differ
immunolog
normal
individu
term
infecti
complic
clearli
howev
immunosuppress
patient
also
develop
complic
underli
diseas
drug
use
treat
underli
process
noninfecti
complic
focu
chapter
review
chapter
patient
increas
risk
infecti
complic
defi
cienci
host
defens
mechan
refer
compromis
host
patient
icu
almost
univers
compromis
either
virtu
underli
diseas
virtu
invas
devic
util
support
monitor
patient
term
immunocompromis
immunosuppress
defect
specifi
calli
involv
immun
respons
often
patient
defi
cient
infl
ammatori
respons
eg
neutropenia
group
categori
immunocompromis
immunosuppress
although
technic
differ
categori
defi
cient
host
respons
patient
icu
often
immunosuppress
result
underli
diseas
therapi
nutrit
statu
chapter
focus
specifi
calli
patient
immunocompromis
immunosuppress
microbi
complic
patient
develop
determin
gener
nonspecifi
c
barrier
innat
immun
acquir
specifi
c
immun
environment
exposur
nonspecifi
c
barrier
includ
anatom
barrier
intact
skin
mucou
membran
chemic
barrier
gastric
acid
urin
ph
fl
ush
mechan
urinari
fl
ow
mucociliari
transport
organ
breach
barrier
encount
nonspecifi
c
innat
host
factor
term
acut
phase
respons
acut
phase
respons
includ
trigger
molecul
effector
molecul
organ
also
encount
acquir
specifi
c
immun
respons
system
includ
mononuclear
phagocyt
antibodi
infect
occur
may
result
normal
fl
ora
colon
mucos
cutan
surfac
infect
may
result
abnorm
fl
ora
invad
replac
normal
fl
ora
environment
exposur
disrupt
barrier
select
pressur
antimicrobi
agent
tabl
list
organ
caus
diseas
specifi
c
anatom
defens
disrupt
individu
normal
microbi
fl
ora
infect
may
also
result
common
defect
infl
ammatori
immunolog
system
exampl
detail
tabl
infl
ammatori
immunolog
barrier
disrupt
primari
diseas
process
eg
tumor
invad
bone
marrow
immunolog
abnorm
associ
aplast
anemia
collagen
vascular
diseas
destroy
cell
either
bone
marrow
peripheri
infl
ammatori
immunolog
mechan
also
disrupt
drug
cytotox
drug
instanc
reduc
neutrophil
number
function
certain
monoclon
antibodi
destroy
lymphocyt
popul
interfer
cytokin
attach
receptor
site
agent
corticosteroid
multipl
effect
neutrophil
lymphocyt
solubl
factor
infect
may
result
organ
usual
pathogen
becom
opportunist
poor
host
defens
mechan
opportunist
infect
defi
ned
occur
enhanc
frequenc
sever
specifi
c
patient
popul
compar
normal
patient
popul
pneumocysti
jiroveci
exampl
never
caus
diseas
immunolog
normal
individu
caus
frequent
episod
pneumonia
certain
immunosuppress
patient
candida
caus
mild
mucos
diseas
normal
patient
receiv
antibacteri
drug
caus
frequent
sever
mucos
patient
impair
cellmedi
immun
recognit
host
defens
mechan
disrupt
enabl
clinician
focu
diagnost
therapeut
prophylact
manag
optim
patient
outcom
instanc
patient
present
sever
hypoxemia
diffus
pulmonari
infi
ltrate
health
care
provid
recogn
prior
splenectomi
major
predisposit
infect
would
focu
diagnost
evalu
empir
therapi
streptococcu
pneumonia
haemophilu
infl
uenza
contrast
patient
major
predisposit
infect
hiv
infect
lymphocyt
count
health
care
provid
would
focu
pneumocysti
jiroveci
pneumonia
cytomegaloviru
cmv
neg
patient
major
predisposit
recent
allogen
stem
cell
transplant
cmvposit
donor
cmv
would
prime
consider
immun
compet
ideal
measur
object
laboratori
paramet
fact
risk
opportunist
infect
patient
hiv
infect
assess
clinic
laboratori
high
degre
accuraci
measur
number
circul
lymphocyt
suscept
cancer
patient
opportunist
bacteri
candida
infect
assess
measur
number
circul
neutrophil
predisposit
patient
certain
congenit
immunodefi
cienci
assess
measur
serum
immunoglobulin
level
unfortun
howev
larg
number
immunodefi
cienci
object
laboratori
measur
valid
predict
risk
infect
moreov
laboratori
measur
must
interpret
context
lymphocyt
count
great
prognost
valu
patient
hiv
infect
patient
popul
neutrophil
count
relev
patient
popul
low
count
associ
disrupt
mucos
surfac
compar
intact
mucosa
thu
laboratori
paramet
must
interpret
context
patient
underli
diseaserisk
alway
easili
manag
measur
one
laboratori
paramet
importantli
patient
multipl
overlap
predisposit
infect
knowledg
infecti
complic
associ
specifi
c
diseas
specifi
c
immun
defect
specifi
c
laboratori
abnorm
help
predict
manag
infecti
complic
howev
specifi
c
diagnosi
establish
patient
knowledg
immun
defect
help
guid
empir
therapi
help
determin
therapi
diagnost
procedur
safe
perform
immunocompromis
patient
defi
nition
suscept
broader
array
pathogen
immunocompet
patient
understand
specifi
c
immun
defect
enorm
help
understand
like
locat
sourc
infect
howev
immun
defect
must
assess
context
specifi
c
diseas
clinic
manifest
hiv
infect
instanc
quit
differ
clinic
manifest
patient
diseas
alter
cellmedi
immun
lymphoma
immun
defect
must
also
interpret
understand
predisposit
infect
usual
multifactori
addit
neutropenia
lymphocyt
deplet
patient
often
impair
mucos
barrier
poor
ciliari
function
breach
skin
ie
cathet
increas
risk
infect
effect
manag
opportunist
infect
requir
understand
sever
basic
tenet
care
diseas
may
present
subtl
symptom
sign
patient
predispos
deterior
precipit
immunocompromis
patient
may
lack
infl
ammatori
andor
immunolog
mediat
clinic
manifest
infect
often
less
promin
less
impress
immunocompet
patient
similar
complic
thu
clinician
must
recogn
even
subtl
chang
skin
color
cathet
site
appear
chest
radiograph
abdomin
examin
may
warrant
aggress
diagnost
evalu
earli
institut
broadspectrum
empir
therapi
although
icu
patient
demand
prompt
attent
vigor
diagnost
therapeut
manag
mani
type
immunosuppress
associ
especi
precipit
clinic
deterior
despit
innocu
present
fever
invari
present
patient
infect
although
fever
invari
present
patient
popul
infect
immunosuppress
patient
notori
develop
infect
absenc
fever
thu
infect
must
consid
part
differenti
diagnosi
among
patient
afebril
syndrom
might
appear
infecti
convers
patient
fever
may
infect
fever
may
manifest
underli
diseas
allerg
respons
drug
underli
neoplast
collagen
vascular
diseas
diagnost
evalu
need
prompt
defi
nitiv
indic
earlier
patient
lifethreaten
infect
may
present
subtl
symptom
sign
progress
rapidli
earli
manifest
merit
aggress
attempt
defi
ne
anatomi
lesion
caus
microbi
pathogen
spectrum
potenti
pathogen
includ
wide
array
microorgan
eg
virus
fungi
protozoa
bacteria
clinician
must
certain
appropri
specimen
obtain
appropri
microbiolog
histolog
test
order
identifi
common
well
uncommon
unusu
pathogen
invas
diagnost
techniqu
bronchoalveolar
lavag
tissu
biopsi
perform
less
hesit
immunolog
normal
patient
patient
often
enhanc
risk
factor
invas
procedur
thrombocytopenia
coagul
factor
defi
cienci
compromis
organ
function
howev
benefi
defi
nitiv
diagnosi
often
outweigh
risk
procedur
perform
experienc
oper
threshold
initi
broadspectrum
empir
therapi
low
patient
deterior
rapidli
suscept
wide
array
microbi
pathogen
clinician
littl
hesit
institut
empir
antimicrobi
therapi
therapi
must
direct
full
rang
bacteri
fungal
viral
protozo
helminth
infect
patient
predispos
therapi
administ
promptli
prefer
within
hour
suspect
infecti
process
clinician
initi
comprehens
regimen
antimicrobi
agent
discontinu
reduc
cultur
result
clinic
event
clarifi
scenario
foreign
bodi
infecti
foci
address
patient
may
need
care
imag
certain
obstruct
viscu
local
collect
drain
imag
appropri
even
sign
symptom
unimpress
similarli
patient
often
multipl
intravascular
cathet
may
need
remov
discuss
chapter
consider
given
augment
immun
infl
ammatori
respons
may
opportun
augment
immunolog
infl
ammatori
respons
administ
pharmacolog
biolog
agent
granulocyt
colonystimul
factor
gcsf
intraven
immunoglobulin
elimin
immunosuppress
drug
reduc
dose
also
improv
patient
prognosi
effi
caci
toxic
therapi
assess
serial
icu
patient
characterist
requir
attent
monitor
assur
adequaci
safeti
therapi
immunocompromis
patient
often
multipl
prior
concurr
insult
renal
hepat
function
often
receiv
multipl
drug
produc
drugdrug
interact
thu
monitor
pharmacokinet
assess
potenti
toxic
especi
import
patient
popul
moreov
respons
therapi
may
less
robust
immunocompet
patient
antigen
titer
pcr
titer
well
serial
imag
studi
import
assur
adequaci
manag
plan
therapi
must
often
continu
longer
immunolog
normal
patient
cytotox
therapyinduc
neutropenia
major
predisposit
infect
count
cellsmm
total
polymorphonuclear
neutrophil
band
increas
suscept
infect
linear
fashion
ie
lower
neutrophil
count
greater
degre
suscept
absolut
neutrophil
count
factor
determin
suscept
howev
patient
cyclic
neutropenia
druginduc
neutropenia
hivinduc
neutropenia
exampl
nearli
suscept
infect
cancer
patient
receiv
cytotox
therapi
import
contributor
suscept
addit
absolut
neutrophil
count
durat
neutropenia
function
capabl
neutrophil
integr
physic
barrier
skin
gastrointestin
mucosa
patient
microbiolog
environ
endogen
exogen
fl
ora
statu
immun
mechan
exampl
patient
vancomycininduc
neutropenia
therapi
staphylococc
infect
may
develop
complic
neutropenia
brief
defens
mechan
otherwis
intact
patient
hivinduc
neutropenia
may
prolong
even
lifelong
neutrophil
count
yet
suffer
seriou
bacteri
complic
presenc
intact
physic
defens
barrier
major
differ
compar
cancer
patient
whose
skin
mucou
membran
disrupt
cytotox
therapi
skin
gastrointestin
tract
portal
entri
infect
control
diminish
host
immunolog
infl
ammatori
defens
thu
patient
hiv
infect
usual
much
lower
risk
bacteri
infect
cancer
patient
despit
compar
neutrophil
count
aerob
gramneg
bacilli
escherichia
coli
klebsiella
pneumonia
pseudomona
aeruginosa
predomin
pathogen
neutropen
patient
anaerob
bacteria
aerob
gramposit
cocci
recogn
less
commonli
aerob
gramneg
bacillu
infect
also
associ
poorer
outcom
infect
gramposit
cocci
given
spectrum
pathogen
organ
seen
era
combin
therapi
usual
advoc
number
reason
propos
justifi
combin
therapi
broad
coverag
potenti
pathogen
prevent
emerg
resist
synergi
gener
principl
reason
concept
base
prefer
use
combin
therapeut
regimen
howev
studi
unequivoc
demonstr
combin
therapi
provid
better
outcom
monotherapi
assum
studi
arm
contain
drug
activ
caus
organ
addit
predict
synergi
prove
diffi
cult
spectrum
caus
pathogen
neutropen
patient
shift
predomin
gramneg
bacilli
major
gramposit
cocci
includ
streptococci
staphylococci
includ
oxacillinresist
staphylococcu
aureu
enterococci
includ
vancomycinresist
enterocci
develop
potent
broadspectrum
quinolon
drug
provid
singl
agent
probabl
provid
compar
outcom
combin
therapi
use
empir
specifi
calli
current
era
choic
singl
combin
regimen
base
predominantli
spectrum
organ
need
cover
rather
attempt
strategi
tri
obtain
potenc
addit
synergist
combin
promptli
initi
broadspectrum
antibacteri
therapi
cancer
patient
febril
neutropen
neutrophil
count
result
cytotox
chemotherapi
standard
practic
febril
neutropen
patient
appar
sourc
infect
evid
initi
antibacteri
regimen
effect
broadspectrum
antibacteri
regimen
consist
two
drug
use
instead
singl
broadspectrum
antibacteri
drug
stabl
lowrisk
patient
outsid
icu
oral
regimen
consid
reason
approach
oral
regimen
would
use
inpati
circumst
would
appropri
highrisk
unstabl
patient
antifung
antivir
drug
gener
use
empir
neutropen
patient
initi
treat
unless
specifi
c
reason
high
suspicion
fungal
viral
process
histor
infecti
caus
fever
found
two
third
febril
neutropen
cancer
patient
specifi
c
caus
organ
identifi
ed
antimicrobi
therapi
modifi
ed
includ
agent
agent
determin
activ
vitro
suscept
test
penetr
site
infect
combin
therapi
advoc
author
specifi
c
compar
empir
therapi
either
gramposit
gramneg
bacteria
although
note
earlier
littl
data
pathogen
indic
combin
regimen
produc
better
outcom
appropri
singl
agent
therapi
gener
narrow
term
spectrum
howev
alter
broadspectrum
coverag
focus
therapi
associ
complic
eg
breakthrough
bacteremia
unless
neutropenia
resolv
whenev
fever
persist
therapi
gener
continu
entir
cours
neutropenia
cessat
antimicrobi
therapi
associ
recurr
bacteremia
result
initi
caus
organ
newli
identifi
ed
pathogen
cours
antibacteri
therapi
usual
minimum
recommend
caus
infect
identifi
ed
therapi
usual
stop
promptli
neutrophil
count
exce
fever
resolv
sourc
ever
identifi
ed
empir
antibacteri
therapi
success
strategi
reduc
morbid
result
bacteri
process
associ
emerg
fungal
infect
well
resist
bacteri
pathogen
candida
aspergillu
organ
particular
becom
major
caus
morbid
mortal
past
decad
fungal
process
diffi
cult
diagnos
alway
associ
detect
fungemia
emerg
fungi
import
pathogen
especi
patient
prolong
neutropenia
led
recommend
empir
antifung
therapi
ad
neutropen
patient
identifi
ed
bacteri
process
defervesc
within
day
empir
antibacteri
therapi
fluconazol
amphotericin
b
compound
eg
liposom
amphotericin
b
often
use
although
echinocandin
certain
azol
voriconazol
use
investig
clinician
patient
receiv
chemoprophylaxi
quinolon
andor
azol
period
intens
neutropenia
immunosuppress
breakthrough
pathogen
like
resist
prophylact
agent
thu
empir
regimen
must
chosen
keen
attent
drug
patient
receiv
recent
past
well
pathogen
previous
colon
infect
patient
fever
neutropenia
requir
aggress
diagnost
effort
identifi
caus
fever
appropri
antimicrobi
agent
use
appropri
procedur
eg
surgic
drainag
remov
foreign
bodi
cathet
perform
regular
physic
examin
necessari
identifi
site
merit
focus
investig
impair
infl
ammatori
respons
fi
nding
examin
may
subtl
knowledg
specifi
c
immunolog
defect
import
cultur
blood
sputum
urin
appropri
bodi
fl
uid
bodi
site
perform
special
microbiolog
approach
use
detect
virus
fungi
helminth
protozoa
bacteria
imag
studi
also
import
intraabdomin
intrathorac
intracerebr
musculoskelet
process
clinic
subtl
may
associ
identifi
abl
organ
bloodstream
grow
array
antigen
nucleic
acid
gene
detect
system
includ
polymeras
chain
reaction
microarray
gene
assay
investig
facilit
diagnosi
antigen
nucleic
acid
detect
system
blood
bodi
fl
uid
use
detect
cryptococcu
histoplasma
hepat
b
c
hiv
mycobacteria
pneumococci
legionella
approach
despit
promis
initi
report
yet
clinic
practic
level
sensit
specifi
citi
cost
expertis
requir
perform
adequ
care
attent
antimicrobi
suscept
pattern
also
import
patient
expos
repeat
cours
antimicrobi
agent
patient
come
contact
contamin
environ
varieti
health
care
set
resist
longer
issu
exclus
aerob
gramneg
organ
concern
anaerob
gramposit
cocci
virus
fungi
protozoa
clinician
must
recogn
pathogen
may
resist
acquir
patient
may
becom
resist
therapi
induc
resist
mechan
drug
concentr
adequ
inhibit
kill
organ
broadspectrum
agent
use
monotherapi
febril
neutropen
patient
activ
aerob
gramposit
cocci
aerob
gramneg
bacilli
includ
p
aeruginosa
potenti
drug
indic
includ
certain
cephalosporin
eg
cefepim
carbapenem
eg
imipenem
meropenem
combin
agent
eg
piperacillintazobactam
ceftazidim
option
chosen
poor
activ
gramposit
cocci
caus
clinician
use
agent
intensivist
must
recogn
howev
monotherapi
regimen
may
appropri
icu
patient
icu
defi
nition
either
unstabl
hemodynam
potenti
lifethreaten
process
diffus
pneumonia
fragil
concurr
process
thu
combin
regimen
prefer
mani
author
icu
set
even
though
studi
clearli
document
superior
outcom
combin
regimen
decad
start
era
microbi
resist
becom
increasingli
import
problem
mani
type
bacteria
includ
aerob
gramposit
cocci
anaerob
well
aerob
gramneg
bacilli
multipl
drug
empir
regimen
like
monotherapi
regimen
includ
agent
activ
offend
pathogen
thu
situat
icu
failur
use
activ
drug
like
lethal
set
enhanc
potenc
logic
goal
combin
therapi
prudent
initi
manag
strategi
thu
ad
vancomycin
linezolid
daptomycin
better
gramposit
coverag
ad
quinolon
better
gramneg
bacillu
coverag
ad
metronidazol
cefepim
would
prudent
patient
popul
pend
result
initi
diagnost
studi
note
howev
although
strategi
logic
studi
shown
convincingli
approach
improv
outcom
substanti
number
febril
neutropen
patient
fail
improv
term
fever
manifest
failur
improv
may
result
poor
immun
respons
need
drainag
necess
remov
foreign
bodi
use
drug
without
activ
caus
organ
noninfecti
process
includ
drug
allergi
ie
fever
result
drug
includ
antimicrobi
agent
potenti
caus
process
need
aggress
reassess
regular
basi
physic
examin
histori
cultur
imag
techniqu
center
add
antifung
therapi
empir
day
day
therapi
patient
remain
febril
fluconazol
liposom
amphotericin
b
caspofungin
voriconazol
may
use
situat
fl
uconazol
would
less
attract
either
patient
receiv
fl
uconazol
prophylaxi
mold
suspect
toxic
profi
le
amphotericin
b
even
liposom
form
led
mani
clinician
prefer
voriconazol
one
echinocandin
ie
caspofungin
micafungin
anidulafungin
empir
antimicrobi
therapi
initi
optim
durat
therapi
complex
issu
depend
type
sever
infecti
process
durat
sever
immunosuppress
especi
neutropenia
caus
bacterium
identifi
ed
minimum
day
therapi
gener
advoc
least
day
administ
neutropenia
resolv
longer
cours
may
requir
certain
set
durat
antifung
therapi
complex
issu
depend
specifi
c
mycosi
locat
extent
diseas
patient
immun
statu
discuss
chapter
use
combin
therapi
fungal
diseas
remain
controversi
common
problem
febril
neutropen
patient
manag
indwel
intravascular
line
gener
line
left
place
initi
examin
site
reveal
indic
infect
blood
cultur
drawn
cathet
although
expert
advoc
draw
cultur
port
cathet
obtain
mani
blood
cultur
often
feasibl
patient
hemodynam
unstabl
fail
respond
promptli
fl
uid
administr
prudent
remov
line
case
infect
cathet
sourc
sepsi
failur
remov
foreign
bodi
situat
probabl
increas
likelihood
unfavor
outcom
blood
cultur
becom
posit
suspicion
high
cathet
sourc
antibacteri
therapi
may
success
set
eg
pathogen
bacteria
rel
sensit
antibacteri
therapi
thu
avoid
need
remov
cathet
situat
suggest
cathet
remov
necessari
includ
hemodynam
instabl
despit
aggress
fl
uid
resuscit
tunnel
infect
infect
result
fungi
rel
antibioticresist
bacteria
p
aeruginosa
major
determin
prognosi
immunolog
statu
patient
prompt
return
neutrophil
number
normal
improv
outcom
use
gcsf
granulocytemonocyt
colonystimul
factor
gmcsf
contraind
underli
diseas
improv
clinic
statu
hasten
return
neutrophil
number
function
granulocyt
transfus
prove
use
clinic
set
inabl
administ
larg
number
cell
adequ
frequenc
manipul
immun
respons
cytokin
cytokin
inhibitor
immunoglobulin
subject
consider
investig
intervent
may
reduc
durat
fever
incid
infect
use
empir
set
clearli
shown
improv
surviv
administ
infect
document
algorithm
manag
fever
neutropen
patient
provid
figur
tabl
suggest
modifi
cation
standard
empir
regimen
certain
common
clinic
scenario
given
experi
frequent
sever
infecti
complic
cancer
patient
neutropenia
logic
attempt
prevent
infect
microorgan
caus
diseas
patient
popul
aris
endogen
gastrointestin
cutan
respiratori
fl
ora
total
protect
environ
probabl
reduc
frequenc
infect
approach
expens
inconveni
tri
prove
consist
benefi
cial
impact
surviv
diffi
cult
thu
isol
rare
use
anymor
expert
enthusiast
place
patient
posit
pressur
room
pathogen
enter
via
particl
droplet
outsid
room
type
isol
clearli
improv
outcom
howev
standard
care
prophylact
bacteri
therapi
also
controversi
system
antibacteri
prophylaxi
system
antifung
prophylaxi
shown
studi
reduc
number
infect
lack
effect
patient
surviv
cost
impact
emerg
resist
made
mani
clinician
reluct
use
select
gastrointestin
decontamin
consist
improv
surviv
thu
recommend
author
unit
state
antipneumocysti
prophylaxi
contrast
highli
effect
suscept
popul
prophylaxi
cmv
highli
effect
welldefi
ned
highrisk
patient
eg
recipi
organ
transplant
either
seroposit
cmv
seroneg
receiv
graft
seroposit
donor
strategi
reduc
period
immunolog
suscept
eg
reduc
durat
neutropenia
ad
gcsf
regimen
reduc
intens
chemotherapeut
regimen
promis
mani
patient
receiv
highli
activ
antiretrovir
therapi
haart
opportunist
infect
complic
cours
hiv
infect
degre
earli
opportunist
infect
continu
occur
howev
three
group
hivinfect
patient
unawar
hiv
statu
develop
clinic
syndrom
unabl
unwil
receiv
appropri
therapi
fail
haart
opportunist
infect
prophylaxi
although
haart
dramat
reduc
incid
opportunist
infect
surprisingli
larg
fraction
patient
either
never
respond
virolog
immunolog
lose
respons
within
fi
rst
month
therapi
patient
domin
viral
quasispeci
highli
resist
current
licens
antiretrovir
drug
like
experi
immunolog
declin
next
year
becom
suscept
opportunist
infect
sever
necrot
mucos
gingiv
add
specifi
c
antianaerob
agent
eg
metronidazol
meropenem
imipenem
piperacillintazobactam
plu
agent
activ
streptococci
consid
acyclovir
ulcer
mucos
gingiv
add
acyclovir
anaerob
coverag
add
fl
uconazol
caspofungin
consid
ad
acyclovir
pneumon
diffus
interstiti
add
trimethoprimsulfamethoxazol
azithromycin
levofl
oxacin
moxifl
oxacin
plu
broadspectrum
antibiot
patient
granulocytopen
perian
tender
includ
anaerob
agent
metronidazol
imipenem
meropenem
piperacillintazobactam
abdomin
involv
add
antianaerob
agent
eg
metronidazol
meropenem
imipenem
piperacillintazobactam
patient
hiv
infect
develop
clinic
diseas
result
three
basic
process
direct
effect
hiv
specifi
c
organ
eg
cardiomyopathi
enteropathi
dementia
immunolog
mediat
process
eg
glomerulonephr
thrombocytopenia
opportunist
infect
tumor
enabl
hivinduc
immunosuppress
hiv
appear
caus
direct
organ
damag
damag
may
mediat
cytokin
lymphocyt
monocyt
infl
ammatori
cell
cardiomyopathi
exampl
profound
lethal
process
lead
icu
admiss
complic
process
patient
present
develop
pulmonari
manifest
short
breath
diffus
bilater
infi
ltrate
chest
radiograph
cardiogen
caus
must
consid
hiv
also
caus
diffus
pneumon
profound
encephalopathi
diffus
enteropathi
patient
compat
syndrom
need
comprehens
evalu
look
specifi
c
opportunist
infect
tumor
especi
specifi
calli
treat
hivcaus
syndrom
hiv
etiolog
remain
diagnosi
exclus
institut
antiretrovir
therapi
appear
benefi
cial
patient
suscept
isol
although
data
regard
effect
hivrel
entiti
larg
anecdot
hivrel
thrombocytopenia
anemia
appear
immunolog
mediat
sever
platelet
count
hemoglobin
gdl
seen
expect
complic
disord
relat
develop
antigenantibodi
complex
may
improv
dramat
institut
antiretrovir
therapi
declin
viral
load
thrombocytopenia
intraven
immunoglobulin
anti
rhd
antibodi
corticosteroid
splenectomi
may
also
use
hemolyt
anemia
also
sever
hemoglobin
level
gdl
seen
promin
manifest
hiv
continu
opportunist
infect
tumor
occur
consequ
hivinduc
immunosuppress
lymphocyt
cell
number
use
marker
predict
occurr
opportunist
infect
patient
hiv
infect
relationship
lymphocyt
count
occurr
opportunist
infect
continu
valid
era
haart
licens
fi
rst
antiretrovir
agent
zidovudin
figur
demonstr
typic
relationship
lymphocyt
count
occurr
opportunist
infect
knowledg
relationship
permit
focus
diagnost
therapeut
prophylact
manag
instanc
patient
hiv
infect
lymphocyt
count
present
diffus
pulmonari
infi
ltrate
diagnost
evalu
empir
antimicrobi
regimen
focu
pneumonia
h
infl
uenza
mycoplasma
legionella
chlamydia
organ
well
common
communityacquir
virus
contrast
patient
lymphocyt
count
evalu
empir
regimen
would
focu
pneumocystosi
cmv
although
previous
mention
process
occur
high
lymphocyt
count
also
occur
lower
lymphocyt
count
keep
mind
lymphocyt
count
use
predictor
suscept
infect
import
perfect
occasion
patient
develop
opportunist
infect
uncharacterist
high
lymphocyt
count
instanc
case
pneumocystosi
occur
lymphocyt
count
greater
clinic
paramet
provid
addit
clue
exampl
oral
candidiasi
previou
opportunist
infect
prior
episod
pneumonia
high
viral
load
independ
risk
factor
occurr
pneumocysti
jiroveci
carinii
pneumonia
pcp
logic
infect
well
frequent
question
whether
hivinfect
patient
prior
lymphocyt
count
nadir
affect
likelihood
opportunist
infect
occur
haart
stimul
lymphocyt
count
rise
specif
patient
lymphocyt
count
receiv
haart
patient
lymphocyt
count
haart
patient
greater
risk
develop
opportunist
infect
anoth
patient
whose
current
lymphocyt
count
whose
nadir
haart
data
suggest
two
patient
compar
risk
ie
current
lymphocyt
count
import
predictor
risk
earlier
nadir
minor
infl
uenc
opportunist
infect
suscept
evalu
differenti
diagnosi
infecti
syndrom
patient
hiv
everi
patient
popul
well
geographi
import
part
histori
tuberculosi
alway
concern
extraordinari
suscept
hivinfect
patient
develop
activ
diseas
mani
urban
set
unit
state
pulmonari
evalu
includ
smear
cultur
tuberculosi
diagnos
appropri
caus
pulmonari
dysfunct
assist
determin
respiratori
precaut
appropri
area
countri
ohio
river
valley
indianapoli
histoplasmosi
common
pneumocystosi
caus
diffus
pulmonari
infi
ltrate
southwestern
unit
state
coccidioidomycosi
must
recogn
caus
pulmonari
infi
ltrate
clinic
present
tuberculosi
histoplasmosi
coccidioidomycosi
process
cmv
clinic
indistinguish
pcp
thu
patient
pulmonari
infi
ltrate
icu
prolong
empir
therapi
discourag
favor
vigor
effort
establish
specifi
c
diagnosi
hivinfect
patient
admit
icu
sever
major
syndrom
respiratori
insuffi
cienci
cerebr
dysfunct
septic
shock
hepat
renal
failur
drug
toxic
howev
patient
hiv
infect
also
come
icu
routin
procedur
routin
postop
care
situat
manag
ordinarili
requir
extraordinari
measur
two
except
first
staff
must
fulli
awar
hiv
transmit
danger
injuri
result
sharp
object
procedur
manag
injuri
involv
sharp
object
contamin
blood
biolog
fl
uid
infect
potenti
infect
patient
second
drug
interact
involv
drug
use
procedur
certain
antiretrovir
drug
import
clinic
consequ
mani
proteas
inhibitor
nonnucleosid
revers
transcriptas
inhibitor
backbon
antiretrovir
therapi
inhibit
enhanc
metabol
drug
depend
cytochrom
system
thu
halfliv
certain
analges
sed
hypnot
prolong
hivinfect
patient
take
ritonavir
exampl
pharmacokinet
effect
also
relev
host
therapeut
agent
use
icu
may
affect
effi
caci
safeti
clinician
need
familiar
interact
select
new
therapi
procedur
clinic
entiti
patient
hiv
infect
develop
sever
pulmonari
dysfunct
common
communityacquir
pathogen
pneumonia
legionella
mycoplasma
chlamydia
adenoviru
infl
uenza
respiratori
syncytium
viru
well
opportunist
virus
fungi
thu
diagnost
evalu
need
comprehens
emphas
direct
smear
sputum
bronchoalveolar
lavag
import
recogn
clinic
present
produc
mani
caus
agent
similar
instanc
histoplasmosi
tuberculosi
nonspecifi
c
interstiti
pneumon
present
ident
pcp
thu
although
empir
diagnosi
empir
therapi
may
reason
initi
approach
patient
hiv
infect
mild
pneumon
approach
usual
appropri
patient
icu
evalu
induc
sputum
fi
rst
step
diagnost
approach
pcp
sensit
mani
hospit
institut
yield
consider
lower
specifi
citi
experienc
laboratori
pathogen
includ
mycobacteria
fungi
routin
bacteria
identifi
ed
sputum
well
intub
patient
respiratori
secret
obtain
deep
intratrach
suction
also
like
use
although
care
studi
induc
sputum
diagnosi
establish
evalu
sputum
intratrach
secret
bronchoscopi
perform
bronchoalveolar
lavag
diagnos
almost
case
pcp
even
patient
receiv
day
empir
therapi
diagnosi
pcp
establish
visual
one
cluster
organ
diagnost
criteria
opportunist
infect
review
chapter
patient
hiv
cmv
merit
special
mention
cultur
sputum
bronchoalveolar
lavag
provid
use
inform
patient
lymphocyt
count
predict
cmv
present
secret
independ
whether
pulmonari
diseas
present
diagnosi
cmv
pneumonia
patient
popul
suggest
cytolog
confi
rmed
presenc
multipl
inclus
bodi
lung
tissu
obtain
transbronchi
open
lung
biopsi
similarli
mycobacterium
avium
complex
mac
hsv
often
found
respiratori
secret
organ
almost
never
caus
pneumonia
patient
hiv
infect
patient
popul
clearli
caus
pneumonia
dearth
cmv
mac
hsv
pneumonia
patient
popul
emphas
point
import
know
publish
literatur
clinic
likelihood
differ
microbi
process
fungal
pneumonia
pcp
gener
diagnos
direct
microscopi
cultur
respiratori
secret
sputum
lavag
candida
organ
almost
never
caus
pneumonia
patient
hiv
infect
frequenc
cryptococcu
histoplasma
blastomyc
coccidioid
organ
caus
pneumonia
depend
geograph
exposur
patient
among
mycos
antigen
detect
techniqu
use
fi
nding
cryptococcu
histoplasma
organ
mycobacteria
frequent
infect
respiratori
tract
patient
hiv
infect
note
earlier
avium
complex
almost
never
caus
pulmonari
dysfunct
patient
popul
acidfast
bacilli
seen
oppos
cultur
respiratori
secret
tissu
tuberculosi
almost
alway
pathogen
kansasii
mycobacteria
less
commonli
caus
diseas
screen
patient
acidfast
bacillu
smear
import
prevent
transmiss
tuberculosi
text
continu
p
consid
part
routin
respiratori
evalu
patient
radiograph
infi
ltrate
area
unit
state
therapi
opportunist
infect
summar
tabl
await
specifi
c
diagnosi
reason
initi
empir
therapi
patient
ill
enough
merit
admiss
icu
patient
lymphocyt
count
greater
azithromycin
ceftriaxon
azithromycin
ampicillinsulbactam
would
reason
choic
patient
lymphocyt
count
cell
levofl
oxacin
moxifl
oxacin
plu
trimethoprimsulfamethoxazol
pentamidin
plu
levofl
oxacin
moxifl
oxacin
would
potenti
regimen
pcp
document
trimethoprimsulfamethoxazol
alway
drug
choic
patient
toler
tabl
list
altern
sulfaintoler
individu
regardless
specifi
c
antipneumocysti
regimen
use
corticosteroid
therapi
indic
patient
present
oxygen
pressur
po
mm
hg
alveolararteri
gradient
higher
mm
hg
patient
initi
po
lower
mm
hg
subgroup
substanti
mortal
corticosteroid
shown
provid
surviv
benefi
corticosteroid
may
provid
rapid
perhap
complet
resolut
pulmonari
manifest
patient
present
better
pulmonari
function
surviv
popul
high
clinic
trial
abl
show
surviv
benefi
expert
concern
corticosteroid
use
associ
reactiv
latent
infect
cmv
tuberculosi
howev
reactiv
lifethreaten
infect
associ
corticosteroid
regimen
patient
aidsassoci
pcp
manag
improv
deterior
day
therapi
median
time
improv
clinic
variabl
day
therefor
chang
therapi
probabl
warrant
day
point
accuraci
diagnosi
reassess
consider
given
repeat
bronchoscopi
transbronchi
biopsi
determin
cmv
fungi
mycobacteria
nosocomi
bacteri
process
present
noninfecti
process
congest
heart
failur
tumor
eg
kaposi
sarcoma
must
also
consid
pneumocystosi
caus
process
identifi
ed
corticosteroid
ad
regimen
alreadi
whether
switch
one
antipneumocysti
agent
anoth
whether
ad
second
agent
help
determin
clinic
trial
human
pneumocystosi
isol
resist
sulfonamid
test
avail
research
center
clinician
add
parenter
pentamidin
trimethoprimsulfamethoxazol
parenter
trimetrex
clindamycinprimaquin
could
use
salvag
regimen
well
patient
improv
day
therapi
specifi
c
chemotherapi
plu
corticosteroid
exceedingli
poor
prognosi
patient
aidsrel
pcp
intub
provid
mechan
ventil
mortal
patient
popul
sever
seri
earli
sinc
era
support
care
improv
treatment
modal
concurr
infecti
noninfecti
process
becom
effect
patient
select
ventilatori
support
probabl
also
improv
patient
multipl
activ
opportunist
infect
substanti
weight
loss
respons
day
therapi
wors
prognosi
ambul
patient
develop
respiratori
failur
third
day
therapi
thu
decis
icu
support
patient
hiv
infect
respiratori
failur
need
individu
basi
realist
assess
prognosi
avail
resourc
prefer
individu
patient
frequent
question
hivinfect
patient
icu
whether
antiretrovir
drug
continu
initi
critic
lifethreaten
ill
although
specifi
c
studi
variou
strategi
author
discourag
use
antiretrovir
drug
icu
drug
interact
drug
toxic
addit
initi
haart
associ
dramat
immun
reconstitut
syndrom
complic
process
brought
patient
icu
final
almost
antiretrovir
drug
commerci
avail
oral
situat
better
discontinu
antiretrovir
drug
day
week
month
rather
risk
poor
absorpt
suboptim
serum
level
latter
would
enhanc
emerg
drugresist
hiv
import
caus
admit
hivinfect
patient
icu
either
seizur
alter
mental
statu
either
result
infecti
neoplast
process
caus
mening
diseas
parenchym
involv
differenti
diagnosi
mening
diseas
includ
pneumococc
staphylococc
mening
cryptococc
mening
tubercul
mening
lymphomat
mening
well
involv
endem
mycos
common
communityacquir
viral
bacteri
process
diffus
central
nervou
system
parenchym
diseas
caus
hiv
progress
multifoc
leukoencephalopathi
occasion
herp
virus
cmv
herp
simplex
viru
focal
mass
lesion
may
caus
toxoplasmosi
lymphoma
less
often
tuberculosi
fungi
convent
bacteri
abscess
nocardia
tumor
caus
focal
lesion
lesion
diffi
cult
distinguish
clinic
radiolog
lymphocyt
count
help
narrow
differenti
diagnosi
csf
brain
tissu
usual
necessari
defi
nitiv
diagnosi
routin
therapi
mani
process
outlin
tabl
toxoplasmosi
deserv
particular
mention
frequenc
toxoplasmosi
occur
mainli
patient
hiv
infect
lymphocyt
count
posit
igg
antibodi
titer
toxoplasma
receiv
trimethoprimsulfamethoxazol
dapson
prophylaxi
patient
present
alter
cognit
focal
motor
sensori
defi
cit
seizur
lesion
may
unifoc
multifoc
usual
enhanc
contrast
invari
true
patient
fi
profi
le
high
risk
toxoplasmosi
compat
present
reason
establish
empir
diagnosi
institut
specifi
c
therapi
sulfadiazin
plu
pyrimethamin
patient
unabl
toler
sulfa
clindamycin
plu
pyrimethamin
corticosteroid
may
need
patient
consider
intracerebr
edema
elev
intracrani
pressur
antiseizur
medic
usual
institut
seizur
occur
rather
prophylact
patient
improv
clinic
radiolog
within
day
patient
fail
improv
stereotact
needl
biopsi
appropri
especi
preval
lymphoma
increas
organ
diffi
cult
see
brain
specimen
obtain
techniqu
patient
hiv
infect
develop
hypotens
result
type
disord
nonhiv
infect
individualssepsi
primari
infect
wound
devic
especi
intravascular
access
devic
fl
uid
deplet
vomit
diarrhea
hemorrhag
gastrointestin
lesion
exampl
common
caus
evalu
hypotens
patient
hiv
infect
must
take
account
factor
particular
patient
popul
suscept
opportunist
infect
undergo
mani
procedur
associ
infecti
complic
receiv
array
drug
cardiovascular
effect
thu
evalu
hypotens
patient
popul
requir
comprehens
thorough
approach
differenti
diagnosi
major
caus
shown
tabl
adren
function
alway
deserv
special
attent
sever
viral
process
fungal
mycobacteri
diseas
hiv
drug
suppress
adren
axi
either
caus
hypotens
exacerb
patient
hiv
infect
typic
receiv
sever
antimicrobi
agent
reduc
likelihood
acquir
opportunist
infect
primari
prophylaxi
term
use
indic
strategi
reduc
likelihood
initi
episod
diseas
process
secondari
prophylaxi
term
use
indic
strategi
prevent
recurr
relaps
chronic
suppress
therapi
ident
secondari
prophylaxi
refer
regimen
continu
initi
therapeut
cours
prevent
relaps
patient
hiv
infect
lymphocyt
count
typic
receiv
antipneumocysti
prophylaxi
trimethoprimsulfamethoxazol
regimen
choic
patient
actual
take
drug
breakthrough
pcp
receiv
consider
protect
toxoplasmosi
certain
routin
bacteri
infect
altern
regimen
includ
monthli
dapson
weekli
dapsonepyrimethamin
daili
aerosol
pentamidin
prophylaxi
avium
complex
recommend
patient
lymphocyt
count
clarithromycin
azithromycin
current
drug
choic
mani
clinician
also
use
fl
uconazol
acyclovir
prophylaxi
reduc
frequenc
fungal
viral
process
respect
although
recommend
issu
cost
pill
burden
emerg
resist
pathogen
isoniazid
prophylaxi
import
patient
tuberculin
skin
test
show
mm
indur
histori
substanti
recent
exposur
transmiss
tuberculosi
patient
patient
patient
staff
staff
patient
urgent
concern
icu
patient
hiv
infect
extraordinarili
suscept
tuberculosi
thu
infect
patient
pose
substanti
risk
especi
hospit
pneumonia
undergo
procedur
high
risk
produc
aerosol
intub
bronchoscopi
sputum
induct
aerosol
pentamidin
treatment
identifi
potenti
infect
patient
earli
place
appropri
isol
tuberculosi
statu
fulli
examin
import
mani
center
patient
syndrom
compat
pulmonari
upper
airway
tuberculosi
maintain
isol
least
three
specimen
respiratori
secret
examin
tuberculosi
hivinfect
health
care
practition
need
care
assess
risk
acquir
tuberculosi
exposur
icu
transmiss
hiv
issu
requir
attent
icu
evid
exist
hivinfect
health
care
profession
infect
patient
regardless
procedur
perform
outsid
two
unusu
event
hiv
patient
pose
risk
health
care
profession
howev
risk
substanti
reduc
educ
strict
monitor
complianc
univers
precaut
proper
equip
almost
hiv
transmiss
occup
set
occur
result
injuri
involv
sharp
instrument
eg
needl
scalpel
risk
injuri
one
case
hiv
transmiss
per
injuri
likelihood
transmiss
individu
accid
depend
amount
viremia
time
accid
latestag
patient
gener
circul
viru
earlystag
patient
natur
accid
author
recommend
immedi
prophylaxi
signifi
cant
injuri
occur
involv
hivinfect
patient
consider
debat
exist
optim
choic
drug
optim
durat
therapi
clear
initi
therapi
within
period
hour
rather
day
best
mani
author
advoc
haart
regimen
situat
patient
health
care
provid
determin
therapi
appropri
continu
week
increasingli
icu
care
organ
transplant
recipi
either
period
immedi
procedur
crisi
occur
day
week
month
year
engraft
manag
type
organ
transplant
recipi
uniqu
featur
depend
whether
bone
marrow
kidney
heart
lung
liver
organ
transplant
laboratori
monitor
provid
use
predict
inform
statu
cellular
immun
humor
immun
neutrophil
number
function
ultim
howev
clinic
experi
necessari
type
organ
transplant
immunosuppress
regimen
predict
like
pathogen
characterist
occur
relat
transplant
procedur
infl
uenc
immunosuppress
therapi
exampl
tempor
pattern
infecti
complic
bone
marrow
transplant
shown
figur
although
fi
gure
use
conceptu
howev
immunosuppress
regimen
chang
rapidli
fi
gure
may
mislead
appli
current
transplant
protocol
organ
transplant
recipi
share
complex
interact
immunosuppress
infect
immunosuppress
usual
necessari
allogen
transplant
permit
graft
surviv
potent
immunosuppress
like
infect
occur
strategi
use
antimicrobi
agent
drug
vaccin
biolog
product
aggress
may
reduc
risk
damag
infect
manner
allow
potent
immunosuppress
better
graft
surviv
approach
may
includ
prophylact
antibacteri
antiretrovir
treatment
well
prompt
empir
therapi
emerg
febril
episod
patient
receiv
hematopoiet
stem
cell
transplant
hsct
solid
organ
transplant
often
receiv
antimicrobi
prophylaxi
acyclovir
hsv
valacyclovir
cmv
fl
uconazol
yeast
voriconazol
yeast
mold
trimethoprimsulfamethoxazol
pcp
quinolon
bacteria
use
variou
combin
differ
transplant
program
agent
dictat
organ
break
caus
diseas
antibiot
suscept
pattern
sever
pathogen
deserv
special
mention
cmv
one
promin
pathogen
solid
organ
bone
marrow
transplant
recipi
diseas
secondari
ie
diseas
result
reactiv
previous
acquir
latent
infect
seroposit
organ
recipi
urban
area
unit
state
popul
seroposit
cmv
thu
transplant
recipi
latent
infect
could
potenti
reactiv
cmv
seroneg
patient
acquir
primari
infect
cmvinfect
organ
cmvinfect
blood
blood
product
cmv
seroposit
individu
develop
superimpos
cmv
diseas
cmv
acquir
seroposit
donor
laboratori
monitor
patient
evid
cmv
diseas
use
dna
amplifi
cation
assay
surveil
cmv
antigen
buffi
coat
smear
import
featur
effort
reduc
morbid
mortal
result
cmv
intensivist
need
understand
interpret
assay
term
start
empir
preemptiv
defi
nitiv
therapi
strategi
reduc
frequenc
cmv
diseas
acyclovir
intraven
oral
ganciclovir
oral
valganciclovir
investig
agent
proganciclovir
immun
globulin
use
mani
program
cmv
diseas
caus
substanti
morbid
mortal
includ
fever
hypotens
pneumon
hepat
glomerul
enter
allograft
injuri
avail
ganciclovir
foscarnet
cidofovir
enabl
condit
treat
success
mani
instanc
although
three
drug
associ
substanti
toxic
whether
immun
globulin
either
immun
globulin
specifi
c
hyperimmun
globulin
add
anyth
potenc
therapeut
regimen
clear
although
product
usual
administ
avail
pcp
report
recipi
type
organ
transplant
organ
transplant
program
use
pcp
prophylaxi
trimethoprimsulfamethoxazol
usual
prophylact
agent
choic
effect
agent
well
toler
reduc
frequenc
urinari
tract
infect
potenti
complic
eg
diseas
result
nocardia
pneumonia
haemophilu
organ
fungal
infect
common
caus
pathogen
chang
chang
prophylact
regimen
use
fl
uconazol
candida
albican
infect
becam
less
common
mold
especi
aspergillu
becam
import
pathogen
fl
uconazoleresist
candida
program
use
voriconazol
prophylaxi
patient
mucormycosi
nonalbican
candida
becom
promin
caus
morbid
thu
clinician
must
know
antifung
prophylaxi
use
order
anticip
complic
occur
mold
infect
diffi
cult
diagnos
serum
galactomannan
assay
yield
specifi
c
inform
test
low
sensit
mold
infect
almost
never
caus
fungemia
thu
diagnosi
depend
cultur
highli
suggest
obtain
sourc
bronchoalveolar
lavag
biopsi
viral
respiratori
infect
requir
particular
mention
treatabl
transmiss
communityacquir
respiratori
virus
adenovirus
coronavirus
infl
uenza
occur
immunocompet
immunosuppress
patient
respiratori
infect
occur
immunocompromis
patient
health
care
profession
need
certain
transmiss
viru
caus
potenti
infect
patient
famili
hospit
staff
respiratori
infect
rsv
deserv
special
attent
hsct
patient
although
rsv
like
communityacquir
virus
caus
diseas
patient
popul
especi
lethal
solid
organ
bone
marrow
stem
cell
transplant
thu
rsv
must
specifi
calli
sought
patient
popul
well
visitor
health
care
provid
spread
highli
suscept
patient
similarli
care
immunosuppress
patient
attent
mycobacterium
tuberculosi
import
pathogen
also
spread
patient
famili
hospit
staff
immigr
unit
state
patient
travel
exposur
tuberculosi
need
consid
differenti
diagnosi
specifi
calli
sought
gene
probe
smear
cultur
appropri
diagnosi
therapi
opportunist
infect
nosocomi
infect
follow
guidelin
given
chapter
choos
therapi
attent
must
focus
toxic
antimicrobi
agent
infl
uenc
outcom
transplant
organ
addit
drug
interact
import
especi
cyclosporin
drug
alter
hepat
metabol
rifampin
rifabutin
fl
uconazol
substanti
infl
uenc
cyclosporin
level
thu
need
use
care
pharmacolog
attent
final
clinician
must
recogn
new
immunosuppress
regimen
chang
prophylact
regimen
chang
spectrum
infecti
complic
mention
earlier
fungal
infect
increasingli
like
caus
speci
c
albican
nonalbican
candida
fusarium
rhizopu
recogn
increas
frequenc
similarli
prophylaxi
valganciclovir
reduc
cmv
diseas
push
diseas
occur
later
later
relat
transplant
procedur
virus
bk
viru
caus
diseas
thu
clinician
need
look
chang
spectrum
pathogen
well
chang
manifest
morbid
mortal
caus
infect
manag
optim
knowledg
patient
specifi
c
defect
immunolog
infl
ammatori
respons
help
predict
opportunist
pathogen
like
occur
icu
increasingli
success
enabl
immunosuppress
patient
surviv
acut
crise
especi
defect
immunolog
infl
ammatori
function
revers
time
replac
therapi
neutropen
patient
gramposit
cocci
becom
frequent
gramneg
bacilli
caus
lifethreaten
ill
resist
antimicrobi
agent
becom
major
problem
includ
bacteria
eg
vancomycinresist
enterococci
penicillinresist
pneumococci
fungi
eg
fl
uconazoleresist
candida
organ
well
pcp
virus
eg
acyclovirresist
herp
simplex
ganciclovirresist
cmv
neutropen
patient
combin
therapi
consid
treat
lifethreaten
bacteri
process
substanti
fraction
hivinfect
patient
pcprelat
respiratori
failur
surviv
mechan
support
discharg
hospit
adjunct
corticosteroid
therapi
indic
respiratori
failur
relat
pcp
tuberculosi
concern
immunolog
abnorm
individu
pulmonari
diseas
special
concern
hivinfect
patient
tuberculosi
case
often
warrant
respiratori
isol
appropri
specimen
evalu
mycobacteria
organ
transplant
recipi
develop
opportunist
infect
rel
predict
point
depend
type
transplant
specifi
c
immunosuppress
regimen
use
